First‐in‐human study of a pharmacological duodenal exclusion therapy shows reduced postprandial glucose and insulin and increased bile acid and gut hormone concentrations

To address the need for noninvasive alternatives to metabolic surgery or duodenal exclusion devices for the management of type 2 diabetes (T2D) and obesity by developing an orally administered therapeutic polymer, GLY‐200, designed to bind to and enhance the barrier function of mucus in the gastrointestinal tract to establish duodenal exclusion noninvasively.

[1]  Jian-jun Yang,et al.  Can we abandon foregut exclusion for an ideal and safe metabolic surgery? , 2022, Frontiers in Endocrinology.

[2]  R. Gabbay,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). , 2022, Diabetes care.

[3]  S. Kothari,et al.  American Society for Metabolic and Bariatric Surgery 2020 estimate of metabolic and bariatric procedures performed in the United States. , 2022, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[4]  E. Huang,et al.  8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[5]  P. Schauer,et al.  Foregut Exclusion Enhances Incretin and Insulin Secretion After Roux-en-Y Gastric Bypass in Adults with Type 2 Diabetes. , 2021, The Journal of clinical endocrinology and metabolism.

[6]  Patrice D Cani,et al.  Mucus barrier, mucins and gut microbiota: the expected slimy partners? , 2020, Gut.

[7]  T. Bækdal,et al.  Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes , 2019, Clinical Pharmacokinetics.

[8]  D. A. Harris,et al.  Comparison of early type 2 diabetes improvement after gastric bypass and sleeve gastrectomy: medication cessation at discharge predicts 1-year outcomes. , 2019, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[9]  P. Siersema,et al.  Adverse Events of the Duodenal-Jejunal Bypass Liner: a Systematic Review , 2018, Obesity Surgery.

[10]  C. Thompson,et al.  Effect of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Patients With Type 2 Diabetes With Obesity: A Meta-analysis With Secondary Analysis on Weight Loss and Hormonal Changes , 2018, Diabetes Care.

[11]  7. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2018 , 2017, Diabetes Care.

[12]  F. Rubino,et al.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. , 2016, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[13]  F. Rubino,et al.  Metabolic Surgery for Type 2 Diabetes: Changing the Landscape of Diabetes Care , 2016, Diabetes Care.

[14]  E. Ravussin,et al.  Could the mechanisms of bariatric surgery hold the key for novel therapies?: report from a Pennington Scientific Symposium , 2011, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[15]  R. Bergman,et al.  Mechanisms Responsible for Excess Weight Loss after Bariatric Surgery , 2011, Journal of diabetes science and technology.

[16]  J. Leyba,et al.  Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass for the Treatment of Type 2 Diabetes in Non-obese Patients: Technique and Preliminary Results , 2011, Obesity surgery.

[17]  F. Knop.  Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? , 2009, Diabetologia.

[18]  B. Geloneze,et al.  Surgery for Nonobese Type 2 Diabetic Patients: An Interventional Study with Duodenal–Jejunal Exclusion , 2009, Obesity surgery.

[19]  D. Cummings.  Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery , 2009, International Journal of Obesity.

[20]  J. Teixeira,et al.  Do Incretins Play a Role in the Remission of Type 2 Diabetes after Gastric Bypass Surgery: What are the Evidence? , 2009, Obesity surgery.

[21]  D. Cummings,et al.  Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. , 2007, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[22]  J. Marescaux,et al.  The Mechanism of Diabetes Control After Gastrointestinal Bypass Surgery Reveals a Role of the Proximal Small Intestine in the Pathophysiology of Type 2 Diabetes , 2006, Annals of surgery.

[23]  Dennis D. Kim,et al.  Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[24]  Dennis D. Kim,et al.  Effectiveness of progressive dose‐escalation of exenatide (exendin‐4) in reducing dose‐limiting side effects in subjects with type 2 diabetes , 2004, Diabetes/metabolism research and reviews.

[25]  F. Rubino,et al.  Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations , 2016, Obesity Surgery.

[26]  D. Power.  Standards of medical care in diabetes. , 2006, Diabetes care.